NCT03987204 is a Phase 1 clinical trial of Ivabradine in Atrial Fibrillation, sponsored by Yale University.

Who is sponsoring NCT03987204?

NCT03987204 is sponsored by Yale University.

What drugs are being tested in NCT03987204?

Interventions in NCT03987204: Ivabradine.

What condition does NCT03987204 study?

NCT03987204 studies Atrial Fibrillation, Atrial Fibrillation, Persistent.

Is NCT03987204 still recruiting?

NCT03987204 is currently completed. Last updated 2 July 2021.

Last reviewed 2021-07-02 · How we verify

NCT03987204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivabradine for Rate Control in Permanent Atrial Fibrillation

Completed Phase 1 Last updated 2 July 2021

What this trial tests

Phase 1 trial testing Ivabradine in Atrial Fibrillation in 4 participants. Completed in 17 September 2019.

Timeline

15 June 2019

Primary endpoint
17 September 2019

17 September 2019

Quick facts

Lead sponsor	Yale University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	15 June 2019
Primary completion	17 September 2019
Estimated completion	17 September 2019
Sites	1 location across United States

Drugs / interventions tested

Ivabradine (IVABRADINE) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Atrial Fibrillation, Persistent — all drugs for Atrial Fibrillation, Persistent →

Sponsor

Yale University

Who can join

Adults 21 to 90, any sex, with Atrial Fibrillation or Atrial Fibrillation, Persistent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ivabradine

Trials testing the same drug.

NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
NCT05481177 — Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort · Phase 4 · unknown

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03987204 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 2 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03987204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing